Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 5Glioblastoma 4Oligodendroglioma 3Gliosarcoma 3Glioma 3Brain Neoplasms 3Astrocytoma 3Prostatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Supratentorial Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Optic Nerve Glioma 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 75Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × lonafarnib × Clear all
NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
5 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡